Prices delayed by at least 15 minutes | Print


Shield Therapeutics PLC (STX)

ORD 1.5P
Sell: 1.3p|Buy: 1.4p|Change: 0.13 (10.20%)

This share can be held in a Dealing accountISALifetime ISAJISASIPPand can be used with Dividend reinvestment

Company profile

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segmentsare based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.

Address

Northern Design Centre Studio 6
3rd Floor, Baltic Business Quarter
Newcastle
GBR
NE8 3DF


Telephone

+44 1915118500


Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.